Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 1 -  
CLINICAL TRIAL PROTOCOL : V0211901  
 
Protocol Number:  V0211901  
Protocol Date:  Original Protocol / 23 April  2020  
   Amendment 1 (version 2.0)/ 5 May 2020  
   Amendment 2 (version 3.0)/12 May 2020  
   Amendment 3 (version 4.0)/ 4 June 2020  
   Amendment 4 (version 5.0)/17 June 2020  
   Amendment 5 (version 6.0)/ 10 July 2020  
   Amendment 6 (version 7.0)/ 25 September 2020  
    
Protocol Title:  Randomized , Placebo -Controlled , Phase 2 S tudy of VERU -111 for the 
Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS -CoV -2) in Patients at High Risk for Acute Respiratory Distress 
Syndrome (ARDS).  
IND number:   149282  
EudraCT number:  Not Applicable  
Clinical Phase:  2 
Study Sponsor:  Veru Inc. 
48 NW 25th St 
Suite 102 
Miami, FL 331 27 
Telephone: (305) 509 -6986  
 
CONFIDENTIAL  
This document is a c onfidential communication of Veru  Inc. All information and data 
contained within this document is confidential. Acceptance of this document constitutes the 
agreement by the recipi ent that no information contained herein may be divulged or disclosed 
to third parties without prior written approval.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 2 - TABLE OF CONTENTS  
1.0 LIST OF ABBREVIATIONS  ................................ ................................ ...... 5 
2.0 PHASE 2 PROTOCOL SUMMARY  ................................ ...........................  6 
3.0 INTRODUCTION  ................................ ................................ ....................  10 
3.1 Background  ................................ ................................ ...............................  10 
3.2 Target Indication and Pharmacologic Activity  ................................ ...............  13 
3.3 Study Rationale  ................................ ................................ ..........................  13 
4.0 STUDY OBJECTIVES  ................................ ................................ .............  14 
4.1 Primary Objectives  ................................ ................................ .....................  14 
4.2 Secondary Objectives  ................................ ................................ .................  14 
4.3 Safety Objective  ................................ ................................ .........................  15 
5.0 STUDY DESIGN  ................................ ................................ ......................  15 
5.1 Treatment Groups and Allocation of Subjects  ................................ ................  15 
5.2 Study Duration  ................................ ................................ ...........................  15 
5.3 Efficacy Endpoints  ................................ ................................ .....................  16 
5.3.1  Primary Endpoint  ................................ ................................ .......................  16 
5.3.2  Secondary Endpoints  ................................ ................................ ..................  16 
6.0 SUBJECT POPULATION  ................................ ................................ ........  17 
6.1 Number of Subjects  ................................ ................................ ....................  17 
6.2 Selection Criteria  ................................ ................................ ........................  17 
6.2.1  Inclusion Criteria  ................................ ................................ ........................  17 
6.2.2  Exclusion Criteria  ................................ ................................ .......................  18 
7.0 STUDY MEDICATION  ................................ ................................ ............  19 
7.1 Enrollment and Blinding  ................................ ................................ .............  19 
7.2 Drug Supply  ................................ ................................ ..............................  20 
7.2.1  VERU -111 Capsules  ................................ ................................ ...................  20 
7.2.2  Placebo Control  ................................ ................................ ..........................  20 
7.2.3  Drug Accountability  ................................ ................................ ...................  20 
7.3 Drug Administration  ................................ ................................ ...................  20 
8.0 STUDY PROCEDURES  ................................ ................................ ...........  21 
8.1 Screening  ................................ ................................ ................................ .. 21 
8.2 Enrollment  ................................ ................................ ................................ . 21 
8.3 Day 1  ................................ ................................ ................................ ........  21 
8.4 Day 2 through Day 21  ................................ ................................ .................  22 
8.5 Day 3, Day 9, and Day 15  ................................ ................................ ...........  22 
8.6 Day 22 ± 3 days (these assessments will also be done at Early Termination or 
Discontinuation from the study)  ................................ ................................ ... 23 
8.7 Day 29 ± 3 days  ................................ ................................ .........................  23 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 3 - 8.8 Follow up vi sits at Day 45 ( ± 3 days)  and Day 60 ( ± 3 days)  (can be 
conducted via phone/teleconference)  ................................ ............................  23 
8.9 Subject Stopping Rules  ................................ ................................ ...............  24 
8.10  Early Discontinuation of Study Treatment  ................................ .....................  24 
8.11  Adverse Events  ................................ ................................ ..........................  25 
8.11.1  Intensity of Adverse Events  ................................ ................................ .........  26 
8.11.2  Test Medication Causality  ................................ ................................ ...........  26 
8.11.3  Serious Adverse Events  ................................ ................................ ...............  27 
8.11.4  Initial Reports  ................................ ................................ ............................  28 
8.11.5  Precautions  ................................ ................................ ................................  28 
8.11.6  Reporting of Adverse Events Associated with Study Drug Overdose, Misuse , 
Abuse or Medication Error  ................................ ................................ ..........  28 
8.12  Concomitant Medications and Concomitant Therapies  ................................ ... 29 
8.13  Prohibited  Medications  ................................ ................................ ...............  29 
8.14  Withdrawal  of Subjects  ................................ ................................ ...............  29 
9.0 STATISTICAL ANALYSIS  ................................ ................................ ...... 29 
9.1 Sample Size Calculation  ................................ ................................ ..............  29 
9.2 Populations  ................................ ................................ ................................  30 
9.3 Efficacy Analyses  ................................ ................................ .......................  30 
9.3.1  Primary Endpoint  ................................ ................................ .......................  30 
9.4 Secondary Analyses  ................................ ................................ ....................  30 
9.4.1  Secondary Endpoints  ................................ ................................ ..................  30 
9.4.1.1  Mean change from baseline in WHO Ordinal Scale for Clinical Improvement at 
Day 15, Day 22 and Day 29  ................................ ................................ .........  30 
9.4.1.2  Proportion of subjects that are Grade 5, 6, 7, or 8 on the WHO Ordinal Scale for 
Clinical Improvement at Day 15, Day 22, and Day 29  ................................ .... 31 
9.4.1.3  Proportion of subjects with normalization of fever and oxygen saturation through 
Day 15, Day 22, and Day 29.  ................................ ................................ ....... 31 
9.4.1.4  Days on mechanical ventilation  ................................ ................................ .... 31 
9.4.1.5  All-cause mortality at Day 15, Day 22, and Day 29  ................................ ........  32 
9.4.1.6  Proportion of patients alive and free of respiratory failure at Day 15, and Day 22 32 
9.4.1.7  Proportion of patients alive and discharged from the ICU at Day 15, Day 22, and 
Day 29  ................................ ................................ ................................ ...... 32 
9.4.1.8  Proportion of patients alive and discharged from hospital at Day 15, Day 22, and 
Day 29  ................................ ................................ ................................ ...... 33 
9.4.1.9  Days in ICU  ................................ ................................ ...............................  33 
9.4.1.10  Days in hospital ................................ ................................ ..........................  33 
9.4.1.11  Proportion of subjects on mechanical ventilation at Day 15, Day 22, and Day 29 33 
9.4.1.12  Mean change from baseline in C -reactive protein at Day 9  ..............................  33 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 4 - 9.5 Interim Analysis  ................................ ................................ .........................  34 
9.6 Pharmacokinetic Analysis  ................................ ................................ ...........  34 
9.6.1  Plasma Sampl e Labels  ................................ ................................ ................  35 
9.7 Safety Analysis  ................................ ................................ ..........................  35 
9.7.1  Data Safety Monitoring Board  ................................ ................................ ..... 35 
10.0  ADMINISTRATION PROCEDURES  ................................ .......................  36 
10.1  Study Conduct and Compliance  ................................ ................................ ... 36 
10.2  Informed Consent  ................................ ................................ .......................  36 
10.3  Protocol Amendments  ................................ ................................ .................  37 
10.4  Protocol Deviations  ................................ ................................ ....................  38 
10.5  Data Handling and Recordkeeping  ................................ ...............................  38 
10.5.1  Data Handling  ................................ ................................ ............................  38 
10.5.2  Data Entry  ................................ ................................ ................................ . 38 
10.5.3  Medical Information Coding  ................................ ................................ ........  38 
10.5.4  Data Validation  ................................ ................................ ..........................  38 
10.5.5  Record Keeping  ................................ ................................ .........................  39 
10.6  Data Quality  ................................ ................................ ..............................  39 
10.7  Regulatory Approval  ................................ ................................ ..................  39 
10.8  Publication Policy  ................................ ................................ ......................  39 
10.9  Clinical Study Report  ................................ ................................ ..................  40 
10.10  Contractual and Financial Details  ................................ ................................ . 40 
10.11  Insurance and Indemnity  ................................ ................................ .............  40 
11.0  REFERENCES  ................................ ................................ .........................  41 
12.0  APPENDICES  ................................ ................................ ..........................  43 
12.1  Appendix A: Clinical Laboratory Tests (local laboratory)  ...............................  43 
12.2  Appendix B: Schedule of Study Evaluations ................................ ..................  44 
 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 5 - 1.0 LIST OF ABBREVIATIONS  
AE Adverse e vent 
ALT  Alanine aminotransferase  
ARDS  Acute respiratory distress syndrome  
AST  Aspartate aminotransferase  
BUN  Blood urea nitrogen  
ECMO  Extracorporeal membrane oxygenation  
eCRF  Electronic Case report form  
ECOG  Eastern Cooperative Oncology Group  
GCP  Good clinical practice  
GGT  Gamma -glutamyl transferase  
IMP Investigational medicinal product  
IRB Institutional review board  
IUD Intrauterine device  
IUS Intrauterine system  
LDH  Lactate dehydrogenase  
LDL  Low density lipoprotein  
LMWH  Low molecular weight heparin  
MedDRA  Medical dictionary of regulatory activities  
NSAID  Nonsteroidal anti -inflammatory drug  
OTC  Over the Counter  
PRN  Pro re nata  – As Needed  
RRT  Renal replacement therapy  
SAE  Serious adverse e vent 
 
 
 
 
 
 
 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 6 - 2.0 PHASE 2 PROTOCOL SUMMARY  
Study 
Number:   
V0211901  
Title:  Randomized , Placebo -Controlled , Phase 2 S tudy of VERU -111 for the 
Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS -
CoV -2) in Patients at High Risk for Acute Respiratory Distress Syndrome 
(ARDS)  
 
Primary 
Objective s: To demonstrate the efficacy of  VERU -111 in the treatment of SARS -Cov-
2 Infection  by assessing its effect on  the proportion of subjects that are 
alive without respiratory failure at Day 29. Respiratory failure is defined as 
endotracheal intubation and mechanical ventilation, extracorporeal 
membrane oxygenation, high -flow nasal cannula oxygen delivery, 
noninvasive positive pressure ventilation, clinical diagnosis of respiratory 
failure with initiation of none of these measures only when clinical 
decision making is driven solely  by resource limitation.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 7 - Secondary 
Objectives:  The secondary objectives /endpoints  on this study are:  
1. WHO Ordinal Scale for Clinical Improvement (8 -point ordinal 
scale) at Day 15, Day 22, and Day 29  
Patient State  Descriptor  Score  
Uninfected  No clinical or virological evidence 
of infection  0 
Ambulatory  No limitation of activities  1 
 Limitation of activities  2 
Hospitalized, Mild disease  Hospitalized, no oxygen therapy  3 
 Oxygen by mask or nasal prongs  4 
Hospitalized, Severe 
disease  Non-invasive ventilation or high -
flow oxygen  5 
 Intubation and mechanical 
ventilation  6 
 Ventilation + additional organ 
support – pressors, RRT, ECMO  7 
Death  Death  8 
 
2. Proportion of subject s with normalization of fever and oxygen 
saturation through Day 15 , Day 22 , and Day 29  
3. Days on mechanical ventilation  
4. Percentage of subject s discharged from hospital by Day 15 (and 
Day 2 2) 
5. All-cause mortality  at Day 15, Day 22, and Day 29  
6. Proportion of patients alive and free of respiratory failure at Day 
15, and Day 22 
7. Proportion of patients alive and discharged from the ICU at Day 15, 
Day 22, and Day 29  
8. Proportion of patients alive and discharged from hospital at Day 15, 
Day 22, and Day 29  
9. Days in ICU  
10. Days in hospital  
11. Proportion of  subject s on mechanical ventilation at Day 1 5, Day 22, 
and Day 29  
12. Assess the pharmacokinetics of VERU -111 on Day 15  
13. Assess the effect of VERU -111 on C -reactive protein (change from 
baseline)  
 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 8 - Safety 
Objective:  To assess the safety and tolerability of VERU -111 
Design:  This study is a multicenter, randomized, placebo -control, efficacy and 
safety study of VERU -111 for the treatment of COVID -19. Subjects will 
receive either 18 mg of VERU -111 or matching placebo orally or through 
nasogastric tube daily for up to 21 days or until the subject is discharged 
from the hospital, whichever comes first.  
The primary efficacy endpoint of the study will be  the proportion of 
subjects that are alive without respiratory failure at Day 29. Respiratory 
failure is defined as endotracheal intubation and mechanical ventilation, 
extracorporeal membrane oxygenation, high -flow nasal cannula oxygen 
delivery, noninvasive  positive pressure ventilation, clinical diagnosis of 
respiratory failure with initiation of none of these measures only when 
clinical decision making is driven solely by resource limitation . 
The total study duration for a subject  from screening  to follow up visit  is 
planned to be  62 days. 
An evaluation of the effect of VERU -111 on  SARS -CoV -2 (COVID -19) 
compared to the placebo control will be evaluated after the last subject  has 
completed Day 22. This will allow for the decision to move to Phase 3 
more quickly if the Phase 2 portion of the study shows  a clinically relevant 
difference in the proportion of subjects that are alive without respiratory 
failure at Day 22 in the VERU -111 treated group s compared to the Placebo  
treatment group and VERU -111 is wel l tolerated in the study.  
Due to the unexpectedly slow recruitment into this study, Veru is 
conducting an interim analysis after the first 24 subject s have completed 
Day 15 or h ave discontinued from the study.  
Subjects:  Approximately, 40 subject s are planned to be randomized at a 1:1 ratio into 
two treatment arms  (20 subjects in the VERU -111 treated group and 20 
subjects in the Placebo treated group ).  
The s ubjects with documented evidence of COVID -19 infection will be 
enrolled.  
Treatments:  Subje cts in the VERU -111 treatment groups will receive standard of care, 
plus oral daily VERU -111 18 mg for 21 days or until released from 
hospital.  
Subjects in the Placebo  treatment group will receive standard of care, plus 
a placebo capsule for 21 days or until released from hospital . 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 9 - Procedures:  
 Potential study participants will undergo a series of screening evaluations 
within 2 days prior to randomization .  Subjects who give written informed 
consent and satisfy the selection criteria will be enrolled into the study.   
The temperature and SpO 2 levels will be taken every 12 hours starting at 
baseline.  
Safety evaluations including  assessment of adverse events  (Days 1 -21, Day 
29, Day 45, and Day 60) , 12-lead electrocardiogram  (single)  (baseline , Day 
15, Day 22 , and Day 29 ) and clinical laboratory results : urinalysis 
(baseline, Day 22, and Day 29 ), hematology (baseline, Day 3, Day 9, Day 
15, Day 22 , and Day 29 ), and serum chemistry  (baseline, Day 3, Day 9, 
Day 15 , Day 22  and Day 29 ). 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 10 - 3.0 INTRODUCTION  
3.1 Background  
Over the last 20 years, a number of viral epidemics have posed a serious global public health 
risk including Severe Acute Respiratory Syndrome coronavirus (SARS -CoV) in 2002 -2003, 
H1N1 Influenza in 2009, and the Middle East Respiratory Syndrome coronavirus (MERS -
CoV) in 2012. Around December 2019, a new viral acute severe respiratory illness emerged. 
In February 2020, the World Health Organizatio n (WHO) announced that this illness is 
caused by a coronavirus termed COVID -19. As it was related to SARS -CoV, it was 
eventually named by the International Committee on Taxonomy of Viruses (ICTV) as SARS -
CoV -2 (Cascella 2020 ). The disease resulting from SARS -Cov-2 infection is called, 
Coronavirus Disease 2019 ( COVID -19). Infection with SARS -CoV -2 and the resulting 
COVID -19 disease  has been declared a global pandemic with over 2,107,450  cases and 
136,992  deaths worldwide as of 18 April 2020 and counting  (April 18 , 2020; 
Worldometers.info) . 
SARS -CoV -2 is an enveloped, nonsegmented, positive -sense, single stranded RNA virus with 
an unusually large RNA genome, a nucleocapsid, and club -like spikes  (S protein)  that project 
from their surface and from which they are named.  It belongs to the betacoronavirus  
category which includes SARS -CoV and MERS -CoV. These viruses have been responsible 
for epidemics with variable severity with both respiratory and extra -respi ratory clinical 
manifestations, highly contagious, and mortality rates between 10 -35% (Cascella 2020 ). The 
coronavirus superfamily ( Coronaviridae ) includes several human pathogens with large RNA 
genomes, e.g. , influenza and viral encephalitis and they are classified into alpha, beta, delta 
and gamma coronavirus families and then further divided into Lineages A, B, C and D. 
SARS -CoV -2 is a Lineage B betacoronavirus  (Gorbalenya 2020 ). 
Viruses h ave efficient mechanisms that take control of their host’s cellular machinery to carry 
out viral replication, assembly and to exit from the cell to spread infectious virions. Given the 
spatial distances between the point of virion entry at the plasma membr ane to the location in 
the cell where RNA replication (nucleus) and viral assembly occur in the ER and Golgi and 
then the newly generated virions have to travel back out to the plasma membrane to egress out 
of the cell, it is no wonder that the virus’s mos t critical task is to hijack the host’s internal 
transportation system, the cytoskeleton  (Ward 2011 ). The cytoskeleton has three major types 
of protein filaments: microfilaments (actin), microtubules (tubulin), and intermediate 
filaments. The principal ones involved in viral replication and trafficking (transport) are 
microtubules and actin since these ar e the two main filament systems involved in cellular 
transport  (Ward 2011 ). 
Microtubules are important for cell shape, transport, motility, and cell division ( Heald 2002 ). 
Microtubules are dynamic lo ng polar fibers/filaments that result from the polymerization of  
and   tubulin heterodimer subunits with a positive end located at the plasma membrane and a 
minus end facing the nucleus at the microtubule organizing center (MTOC). From the MTOC, 
microtu bule fibers radiate out from the nuclear area towards the periphery of the cell. 
Microtubules are dynamic network systems, meaning that, they undergo rapid polymerization 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 11 - (add  and   tubulin subunits heterodimers) to grow, and subsequent rapid depolymeri zation 
(remove  and   tubulin subunits heterodimers) to shrink. This “dynamic” growing and 
shrinking serves the constantly changing transportation requirements of the cell. Large 
macromolecules, like viruses, engage with specialized motor proteins (kines ins and dyneins) 
(Dohner 2005 ; Biswas 2014 ; Han 2012 ; Hara 2009 ). Kinesins and dyneins attach, carry, and 
move the virus cargo up and down these microtubule tracks to travel long distances to reach 
the different compartments within the cell  (Ward 2011 ; Simpson 2020 ; Cooper 2000 ). 
Microtubule based tr ansportation is a critical aspect of viral replication  (Naghavi 2017 ; 
Dohner 2005 ). In fact, viral infection or expression of viral proteins alters the organization of 
the microtubular networks t o serve their need to replicate and spread infectious virion. 
Microtubules not only facilitate infection, but microtubules are actively manipulated by 
viruses ( Naghavi 2017 ).  Furthermore, microtubule inhibiting agents that d isrupt microtubule 
networks suppress viral infection  (Rudiger 2016 ). 
Virus -cell surface interactions, virus entry and internalization -  
Although microtubules are located within the cell, they are able to  influence the viral infection 
from the onset. Viruses utilize specific sites and proteins to attached to the cell surface. The 
spatial organization of these surface receptors and entry factors are controlled in part by the 
polarization of the microtubular  array  (Naghavi 2017 ). When added early, nocodazole, a 
microtubule depolymerizing drug, decreased mouse hepatitis coronavirus virus infection by 
affecting plasma membrane entry by endocytosis ( Burkard 2014 ). There are apparently other 
ways that entry and internalization may occur as human coronavirus NL63 internalization and 
vesicle entry was not affected by nocodazole  (Milewska 2018 ). 
In the case of SARS -CoV, the first stage of interaction with the microtubule cytoskeleton 
occurs when the Spike (S) protein mediated attachment to the cell surface  (Ren 2015 ). After 
binding, the virus particles actively rearrange the cytoskeleton by regulati ng the 
FAK/Cofilin/Rac/Cdc42 pathway  (Lv 2019 ).  
Virus intracellular transport via microtubules to the perinuclear region - 
Many viruses require microtubules at cell entry for efficient nuclear targetin g (Dohner 2005 ). 
Vesicular transport occurs via microtubule trafficking and the corresponding specialized 
motor proteins. In the case of the Mouse Hepatitis Coronavirus Virus, the early secretory 
pathway is important in the forma tion of the replication complex  (Knoops 2010 ; Oostra 
2007 ). Intracellular transport of the endocytosed vesicles containing coronavirus utilizes S -
protein bound to  - tubulin on microtubules to lo cate to the perinuclear region of the cell.  
Viruses can also modulate microtubular dynamics to promote rapid transport to nucleus 
(Naghavi 2017 ; Suomalainen 2001 ).  Coronaviruses may also h ave interactions of S proteins 
with the specialized motor proteins like kinesins and dyneins  (Rudiger 2016 ).  
Virion replication and assembly and egress of infectious viral particles out of the cell - 
Virus particle assembly occurs in the ER -Golgi intermediate compartment (ERGIC) and is 
orchestrated by the M protein. M provides the scaffold for virion morphogenesis and M -S and 
M-N interactions facilitate the recruitment of structural components to the a ssembly site. 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 12 - Coronavirus particles budding into the ERGIC are transported in smooth walled vesicles and 
trafficked via microtubules for release by exocytosis. Host factors, specifically, the 
interactions between the cytoskeleton and other structural prote ins are essential in this 
process. Interactions between tubulin and the cytosolic domain of the S protein of human 
coronavirus -229E, human coronavirus -NL63, and TGEV are required for successful assembly 
and release of viral particles  (Reviewed in Fung 2019 ). RNA viruses utilize diverse structures 
within the cytoskeleton for their replication which rely on microtubules to form and function 
(Naghavi 2017 ). Nocodazole, a microtubule depolymerizing agen t, blocks the movement and 
fusion of capsids and nucleoprotein particles to the budding ER/Golgi compartments to form 
virions as well as the secretory microtubule trafficking to egress new virions resulting in 
reduced virus yields  (Eichwald 2012 ; Criglar 2014 ; Dohner 2005 ).   
To evaluate early assembly events, alpha (HCoV -229E, HCoV -NL63, and TGEV) and beta 
(SARS -CoV) coronaviruses S proteins were treated with nocod azole. The pharmacological 
action of nocodazole is the inhibition of tubulin polymerization . Untreated cells had long and 
filamentous tubulin structures (microtubules) and the S protein accumulated near the nucleus 
(ERGIC) and less S protein distributed in the cytosol, whereas the nocodazole treated cells 
had dispersed and patchy tubulin fragments and the S proteins were “differentially 
distributed”, or scattered throughout the cytoplasm  (Rudiger 2016 ). Also, fol lowing 
nocodazole treatment, M protein amount was decreased and there was a reduced 
colocalization of S and M proteins  (Rudiger 2016 ). Nocodazole treatment resulted in both a 
significant reduction in viral particles and these  particles had very little S protein, and thus, 
the virions were less infectious as well  (Rudiger 2016 ). In fact, nocodazole treatment at all 
time points resulted in significantly lower virus titers in cell culture supernatan t versus 
untreated infected cells  (Rudiger 2016 ).  
In summary, tubulin interacts with the cytoplasmic domain of alphacoronavirus  and 
betacoronavirus  SARS -CoV spike S proteins.  Rudiger et al. ( 2016) conclude that the 
reduction in infectious virus titer following treatment with a drug that causes microtubule 
depolymerization is mainly because there is less S protein present at the assembly site due to 
impaired S protein -microtubule transport and t hat the incorporation process of S protein itself 
into virions is tubulin -dependent. Furthermore, disruption of microtubule trafficking impaired 
the egress of these poorly assembled virions with less surface spike S proteins, less infectious, 
out of the ce ll. A microtubule depolymerizing agent may be effective in treating in treating 
coronavirus infection to disrupt microtubule trafficking critical for virus replication cycle.  
Colchicine -like Activity  
The central mechanism of colchicine clinical anti-inflammatory and anti -viral activities is 
based on its ability to bind the “colchicine binding” sites on alpha and beta tubulin which 
when incorporated into microtubule block subsequent microtubule polymerization 
(Slobod nick 2018 ). Inhibition of tubulin polymerization is responsible for the effects of 
colchicine on cell migration, cytokine release, and intracellular trafficking (antiviral) and 
disruption of inflammatory cell activities seen for acute gout and familial Mediterranean 
fever. Colchicine modulates leucocyte mediated inflammatory activities including inhibition 
of leucocyte production of superoxides and release of various cytokines and pyrogens 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 13 - (Slobodnick 2018 ). Colchicine -like agents may be useful to treat the “cytokine storm” seen 
with SARS -CoV 2. IL -18 is a member of the IL -1 cytokine family and unopposed elevated 
levels of IL -18 concentrations have been associated with macrophage activation syndrome 
and poor clinical outc omes in severe inflammatory and septic shock conditions  (Verweyen 
2020 ). Interestingly, colchicine abrogates IL -1 and IL -18 overexpression by reducing its 
transcription to reduce severe inflammation and septic shock. Verwey en et al. ( 2020 ) also 
showed that colchicine as well as nocodazole abrogated IL18 expression confirming that 
microtubule depolymerization is the mechanism.  
3.2 Target Indication and Pharmacologic Activity  
VERU -111 is orally bioavailable bis -indole that binds the “colchicine binding site” of  and  
tubulin and inhibits tubulin polymerization at low nanomolar concentrations. VERU -111 is 
neither a substrate for MDRs including P -gp, MRPs, and BCRP, nor CYP3A4.  VERU -111 
also decreases the transcription of I, III, and IV-tubulin isoforms  (Li 2012 ). VERU -111 
was initially developed as an antiproliferative agent to treat malignancy. In preclinical animal 
models and confirmed in a Phase 1b/2 study in 39 men with metastatic prostate cancer, 
VERU -111 has a good safety  profile  as it does not cause neutropenia or myelosuppression 
and is well tolerated  (clinical data on file  at Veru Inc. , Li 2012 ; Chen 2012 ). The Phase 1b 
study is ongoing with some men being treated with high daily doses of VERU -111 for greater 
than a year. In vivo , VERU -111 disrupts the microtubule filaments similar to nocodazole and 
colchicine, the central mechanism that c ontributes to both their antiviral and anti -
inflammatory activities.  
3.3 Study Rationale  
Based on VERU -111’s mechanistic similarities to other microtubular depolymerizing agents 
as well as its preclinical and clinical experience, VERU -111 could have a two -pronged 
approach to the treatment of SARS -CoV -2 (COVID -19) virus infection and the debilitating 
and sometimes lethal respiratory effects of the virus.  
1. As an antiviral, it would have direct effects on S protein -microtubule trafficking with 
the potential to reduce the production of infectious virions particularly affecting viral 
replication and assembly and virion egress.  
2. As an anti -inflammatory agent, it  may reduce virally induced severe inflammation in 
the respiratory system and reduce the incidence of cytokine storm and septic shock 
that can occur in subject s that progress.  
VERU -111 appears to be an appropriate candidate to enter clinical development for the 
treatment of SARS -CoV -2 (COVID -19) infection. In the absence of an effective treatment 
and the progression of the ongoing global pandemic  and potentially future similar viral 
epidemic infections , Veru is initiat ing a Phase 2 clinical de velopment program of VERU -111 
for the treatment of SARS -CoV -2 infection  (COVID -19). 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 14 - 4.0 STUDY OBJECTIVES  
4.1 Primary Objective s 
To demonstrate the efficacy of  VERU -111 in the treatment of SARS -CoV -2 infection  by 
assessing its effect on  the proportion of subjects t hat are alive without respiratory failure at 
Day 29. Respiratory failure is defined as endotracheal intubation and mechanical ventilation, 
extracorporeal membrane oxygenation, high -flow nasal cannula oxygen delivery, noninvasive 
positive pressure ventilati on, clinical diagnosis of respiratory failure with initiation of none of 
these measures only when clinical decision making is driven solely by resource limitation.  
4.2 Secondary Objective s 
The secondary objectives/endpoints on this study are:  
1. WHO Ordinal Scale for Clinical Improvement (8 -point ordinal scale) at Day 15, Day 
22, and Day 29  
Patient State  Descriptor  Score  
Uninfected  No clinical or virological evidence 
of infection  0 
Ambulatory  No limitation of activities  1 
 Limitation of activities  2 
Hospitalized, Mild disease  Hospitalized, no oxygen therapy  3 
 Oxygen by mask or nasal prongs  4 
Hospitalized, Severe 
disease  Non-invasive ventilation or high -
flow oxygen  5 
 Intubation and mechanical 
ventilation  6 
 Ventilation + additional organ 
support – pressors, RRT, ECMO  7 
Death  Death  8 
a. Change in mean WHO Ordinal Scale for Clinical Improvement at Day 15  
b. Proportion of subjects that progress to Grade 5, 6, 7, or 8 on the WHO Ordinal 
Scale for Clinical Improvement at Day 15  
c. Proportion of subjects that progress to Grade 5, 6, 7, or 8 on the WHO Ordinal 
Scale for Clinical Improvement at Day 22  
d. Proportion of subjects that progress to Grade 5, 6, 7, or 8 on the WHO Ordinal 
Scale for Clinical Improvement at Day 29  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 15 - e. Change in mean WHO Ordinal Scale for Clinical Improvement at Day 22  
f. Change in mean WHO Ordinal Scale for Clinical Improvement at Day 29  
2. Proportion of subjects with normalization of fever and oxygen saturation through Day 
15, Day 22, and Day 29  
3. Days on mechanical ventilation  
4. Percentage of subjects discharged from hospital by Day 15 (and Day 22)  
5. All-cause mortality at Day 15, Day 22, and Day 29  
6. Proportion of patients alive and free of respiratory failure at Day 15, and Day 22 
7. Proportion of patients alive and dischar ged from the ICU at Day 15, Day 22, and Day 
29 
8. Proportion of patients alive and discharged from hospital at Day 15, Day 22, and Day 
29 
9. Days in ICU  
10. Days in hospital  
11. Proportion of subjects on mechanical ventilation at  Day 1 5, Day 22, and Day 29  
12. Assess the ph armacokinetics of VERU -111 on Day 15  
13. Assess the effect of VERU -111 on C -reactive protein from baseline to Day 9  
4.3 Safety Objective  
To assess the safety and tolerability of VERU -111 
5.0 STUDY DESIGN  
5.1 Treatment Groups and Allocation of Subjects  
This randomized, placebo -control  clinical study consists of two treatment arms : VERU -111 
18 mg treated group, and Placebo  treated  group. Subjects will be randomized in a 1:1 fashion  
to the VERU -111 treated group and Placebo treated group, respectively . 
All pati ents will receive standard of care for the treatment of SARS -CoV -2 infection 
(COVID -19). 
5.2 Study Duration  
The study will require  that each subject in the VERU -111 treated group s receive  18 mg daily 
oral dose of VERU -111 or placebo for up to 21  days (Day 21) with final on study efficacy 
assessments done on Day 2 9 with safety assessments continuing to Day 60 of the study.  The 
total duration of the study for a subject  in the study from screening to follow -up visit  
(approximately Day 60 on study ) will b e approximately  62 days.   
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 16 - 5.3 Efficacy Endpoints  
5.3.1 Primary E ndpoint  
The primary endpoint for the study is  the proportion of subjects that are alive without 
respiratory failure at Day 29. Respiratory failure is defined as endotracheal intubation and 
mechanical ventilation, extracorporeal membrane oxygenation, high -flow nasal cannula 
oxygen delivery, noninvasive positive pressure ventilation, clinical diagnosis of respiratory 
failure with initiation of none of these measures only when clinical decision  making is driven 
solely by resource limitation.  
5.3.2 Secondary E ndpoints  
The secondary endpoints on this study are:  
1. WHO Ordinal Scale for Clinical Improvement  (8-point ordinal scale)  
Patient State  Descriptor  Score  
Uninfected  No clinical or virological evidence 
of infection  0 
Ambulatory  No limitation of activities  1 
 Limitation of activities  2 
Hospitalized, Mild disease  Hospitalized, no oxygen therapy  3 
 Oxygen by mask or nasal prongs  4 
Hospitalized, Severe 
disease  Non-invasive ventilation or high -
flow oxygen  5 
 Intubation and mechanical 
ventilation  6 
 Ventilation + additional organ 
support – pressors, RRT, ECMO  7 
Death  Death  8 
1. Proportion of subjects that are Grade 5, 6, 7, or 8  on the WHO Ordinal Scale for 
Clinical Improvement  at Day 15  
2. Proportion of subjects that progress to Grade 5, 6, 7, or 8  on the WHO Ordinal Scale 
for Clinical Improvement  at Day 22  
3. Proportion of subjects that are Grade 5, 6, 7, or 8  on the WHO Ordinal Scale for 
Clinical Improvement  at Day 29  
4. Change in mean WHO Ordinal Scale for Clinical Improvement at Day 15.  
5. Change in mean WHO Ordinal Scale for Clinical Improvement at Day 22  
6. Change in mean WHO Ordinal Scale for Clinical Improvement at Day 29  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 17 - 7. Proportion of subject s with normalization of fever and oxygen saturation through Day 
15. This will be a composite of fever normalization maintained for at least 24 hours 
AND peripheral capillary oxygen saturation (SpO 2) >94% sustained for 24 hours.  
8. Proportion of subjects with normali zation of fever and oxygen saturation through Day 
22. This will be a composite of fever normalization maintained for at least 24 hours 
AND peripheral capillary oxygen saturation (SpO 2) >94% sustained for 24 hours.  
9. Proportion of subjects with normalization of fever and oxygen saturation through Day 
29. This will be a composite of fever normalization maintained for at least 24 hours 
AND peripheral capillary oxygen saturation (SpO 2) >94% sustained for 24 hours.  
10. Days on mechanical ventilation   
11. All-cause mortali ty at Day 15  
12. All-cause mortality at Day 22  
13. All-cause mortality at Day 29  
14. Proportion of patients alive and free of respiratory failure at Day 15  
15. Proportion of patients alive and free of respiratory failure at Day 22  
16. Proportion of patients alive and discharg ed from the ICU at Day 15  
17. Proportion of patients alive and discharged from the ICU at Day 29  
18. Proportion of patients alive and discharged from hospital at Day 15  
19. Proportion of patients alive and discharged from hospital at Day 22  
20. Proportion of patients aliv e and discharged from hospital at Day 29  
21. Days in ICU  
22. Days in hospital  
23. Proportion of subjects on mechanical ventilation at  Day 1 5 
24. Proportion of subjects on mechanical ventilation at  Day 22 
25. Proportion of subjects on mechanical ventilation at  Day 29 
26. Pharmacok inetics of VERU -111 on Day 15  
27. Change in mean C -reactive protein from baseline to Day 9. 
6.0 SUBJECT POPULATION  
6.1 Number of Subjects  
Approximately, 40 subjects are planned to be randomized  at a 1:1 ratio into t wo treatment 
arms  (20 subjects in the VERU -111 treated group and 20 subjects in the Placebo treated 
group ).  
The subjects with documented evidence of COVID -19 infection (by standard diagnostic 
method) will be enrolled. Subjects will be at high risk for the development of ARDS . 
6.2 Selection Criteria  
6.2.1 Inclusion C riteria  
Subject s accepted for this study must:  
1. Provide informed consent  
2. Be able to communicate effectively with the study personnel  
3. Aged ≥18 years  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 18 - 4. Severe Acute Respiratory Syndrome Coronavirus (SARS -CoV -2) infection confirmed by 
polymerase chain reaction (PCR) test  
5. Patients at high risk for ARDS, with known comorbidities for being at high risk, such as, 
Asthma (moderate to severe), Chronic Lung Disease, Diabetes, Chronic Kidney Disease 
being treated with dialysis, Sev ere Obesity (BMI ≥40), 65 years of age or older, primarily 
reside in a nursing home or long -term care facility, or immunocompromised.  
6. Peripheral capillary oxygen saturation ( SpO 2) ≤ 94% on room air at screening . If patient 
is on oxygen therapy at the time of presentation for screening and the SpO 2 levels were 
≤94% prior to introduction to oxygen therapy  with proper documentation example EMT 
notes or ER/ED notes , then the patient is considered to have met this inclusion criterion. 
If patient is on oxygen the rapy at the time of presentation for screening and the SpO 2 
levels prior to introduction to oxygen therapy are unknown, the patient may be 
considered to have met this inclusion criterion if oxygen therapy is removed and the 
SpO 2 levels fall to ≤94%, then t he patient is considered to have met this inclusion 
criterion. However, removal of the oxygen therapy should only be done if it is considered 
medically reasonable.  
7. Subjects must agree to use acceptable methods of contraception  
• If subject is female or the m ale subject’s partner could become pregnant , use 
acceptable methods of contraception from the time of the first administration of 
study medication until 6 months following administration of the last dose of 
study medication. Acceptable methods of contracep tion are as follows: Condom 
with spermicidal foam/gel/film/cream/suppository [i.e. , barrier method of 
contraception] , surgical sterilization (vasectomy with documentation of 
azospermia) and a barrier method {condom used with spermicidal 
foam/gel/film/cream /suppository} , the female partner uses oral contraceptives 
(combination estrogen/progesterone pills), injectable progesterone or subdermal 
implants and a barrier method (condom used with spermicidal 
foam/gel/film/cream/suppository ) 
• If female subject  or the female partner of a male subject  has undergone 
documented tubal ligation (female sterilization ), a barrier method (condom used 
with spermicidal foam/gel/film/cream/su ppository ) should also be used  
• If female subject  or the female partner of a male subject  has undergone 
documented placement of an intrauterine device (IUD) or intrauterine system 
(IUS) , a barrier method (condom with spermicidal 
foam/gel/film/cream/suppository ) should also be used  
8. Subject i s willing to comply with the requirements of the protocol through the end of the 
study  
6.2.2 Exclusion C riteria  
Any of the following conditions are caus e for exclusion from the study:  
1. Known hypersensitivity or allergy to colchicine  
2. Participation in any other clinical trial of an experimental treatment for COVID -19. 
Convalescent plasma and remdesivir are allowed in this study.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 19 - 3. Concurrent treatment with other experimental agents with actual or possible direct acting 
antiviral activity  against COVID -19 is prohibited < 24 hours prior to study drug dosing  
(except standard of care) . Remdesivir and convalescent plasma are allowed in the study . 
4. Requiring ventilation + additional organ support – pressors, RRT, ECMO  (WHO Ordinal 
Scale for Clinical Impr ovement – Score of 7) and patients requiring ventilation with a 
WHO Ordinal Scale for Clinical Improvement – Score of 6 for >5 days at screening .  
• Patients on ventilation with a WHO Ordinal Scale for Clinical Improvement 
Score of 5 (non-invasive ventilatio n or high -flow oxygen) are allowed into the 
study.  
• Patients on ventilation with a WHO Ordinal Scale for Clinical Improvement 
Score of 6 (intubation and mechanical ventilation) for less than five (5) days are 
allowed into the study.  
5. Alanine Aminotransferas e (ALT) or aspartate aminotransferase (AST) > 2 X upper limit of 
normal (ULN)  
6. Total bilirubin > ULN  
7. Creatinine clearance < 60 mL/min  
8. Documented medical history of liver disease, including but not limited to, prior diagnosis 
of hepatitis of any etiology, cir rhosis, portal hypertension, or confirmed or suspected 
esophageal varices  
9. Moderate to severe renal impairment  
10. Hepatic impairment  
11. History of hepatitis  
12. Any comorbid disease or condition (medical or surgical) which might compromise the 
hematologic, cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or 
central nervous system; or other conditions that may interfere with the absorption, 
distribution, metabolism or excretion of study drug, or would place the subject at i ncreased 
risk 
13. Participants must agree to refrain from prolonged exposure to the sun or agree to use at 
least SPF 50 on all exposed skin and protective clothing during prolonged sun exposure 
throughout participation in this study and/or treatment with VERU -111. 
7.0 STUDY MEDICATION  
7.1 Enrollment and Blinding  
The study will be a randomized , double -blind, placebo -controlled  study . The study will be 
unblinded when the last patient has completed the Day 29 assessments.  
An emergency code break will be available to the investigator / pharmacist / investigational 
drug storage manager. This code break option in IWRS may only be disclosed  in emergency 
situations when the identity of the trial drug must be known to the investigator in order to 
provide appropriate medical treatment or if required to assure safety of trial participants. If the 
code break for a patient is opened, the sponsor a nd CRO will be informed immediately via 
IWRS notification. The reason for the IWRS unblinding of the subject must be documented 
on the appropriate eCRF page along with the date and the initials of the person who broke the 
code.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 20 - 7.2 Drug Supply  
7.2.1 VERU -111 Capsule s 
VERU -111 18 mg dose will be supplied as capsules containing 18 mg of VERU -111. 
Capsules will be supplied in bottles containing 21 capsules in each bottle.  Patients will take 
one VERU -111 capsule per day.   
The VERU -111 capsules  should be stored at controlled room temperature, 20°C to 25°C 
(68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F).  
7.2.2 Placebo Control  
Placebo capsules contain zero  (0) mg VERU -111 drug substance  will be supplied in bottles 
containing  21 capsules each. The placebo capsules will contain only anhydrous lactose , USP . 
These capsules are identically appearing to the VERU -111 capsules. Patients will take one 
Placebo capsule per day.  
The Placebo capsules should be stored at controlled room te mperature, 20°C to 25°C (68°F to 
77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F).  
7.2.3 Drug A ccountability  
Subject s should not take a replacement dose if a dose is missed. Study medication should not 
be taken more than once a day.  
The pharmacists or other site personnel as delegated by the Investigator are responsible for 
accountability of all used and unused study drug supplies. A study drug d osing log should be 
kept current and should contain the dates and times drug d osing  the subjec t, the subject’s 
identification (i.e., subject number), the initials of the dispensing persons . Veru Inc. , shall be 
immediately notified of any unexpected occurrences during the dispensing  or dosing  of study 
drug.  
7.3 Drug Administration  
Study drug  should be t aken daily at approximately the same time every day with 
approximately 240 mL (a full glass) of non -alcoholic liquid (drink). Dosing should occur 
within 30 minutes to 1  hour prior to the start of the morning meal .  Subjects will take the 
entire daily dose at on ce. In subject s with a nasogastric feeding tube, the contents of the 
capsule s may be emptied into the tube and appropriately flushed through the tube.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 21 - 8.0 STUDY PROCEDURES  
8.1 Screening  
Potential subjects will be screened for this study in the 2 days prior to enrollment . The 
following activities will be conducted at screening:  
1. Signed informed consent  and HIPAA form  will be obtained prior to any study -specific 
procedures and a copy of the signed consent form will be given to the subject.  
2. Assess subject eligibility for inclusion into this study based on protocol 
inclusion/exclusion criteria.  
3. Medical history will be ob tained, including diagnosis of COVID -19 infection (date of 
diagnosis ), details and dates of treatments received, documentation of symptoms 
related to COVID -19 infection.  
4. The use of any medications will be recorded. This will include medications currently 
being taken and those taken since COVID -19 symptoms started . Over -the-counter 
(OTC) medications as well as medications taken on an as -needed basis (PRN) should 
be recorded.  
5. Pregnancy test (female subjects only)  
6. Vital signs (temperature/pulse/supine , if poss ible, blood pressure)  
7. SpO 2 
8. Physical examination including height  and weight  
9. Electrocardiogram - 12 lead (single)  
10. Clinical Laboratory Tests  
• Hematology  (Appendix A ) 
• Serum chemistry  (Appendix A ) 
• Urinalysis  
8.2 Enrollment  
Enrollment should be done after the subject has completed the screening assessments and 
after it has been determined that the subject meets all the inclusion and exclusion criteria.  
Subject will be randomized into one of two treatment groups . 
8.3 Day 1  
The Day 1 visit  assessments will se rve as the baseline assessments.  
1. The medical history should be reviewed and updated to include any changes occurring 
since the screening visit.  This will i nclude the following:  
a. Number of days from onset of COVID -19 symptoms to Day 1  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 22 - b. Specific reason for hospitalization  
2. Assessment of eligibility  
3. Vital signs (temperature/pulse/supine , if possible,  blood pressure)  
4. SpO 2 
5. Physical examination  (including weight)  
6. Chest X -ray or Computed Tomography (CT) scan  
7. Clinical Laboratory Tests  
a. Hematology ( Appendix A ) 
b. Serum chemistry  (Appendix A ) 
c. Urinalysis  
8. Record the usage of  any concomitant medications and ongoing treatments . 
9. Adverse events (ongoing on Day 1)  
10. First dose of study drug  
11. Temperature  and SpO 2 every 12 hours after dosing  
8.4 Day 2 through Day 21 
The following assessments will be conduc ted on each of Day 2 to Day 21 
1. Temperature  and SpO 2 every 12 hours  
2. Vital signs (temperature/pulse/supine, if possible, blood pressure)  
3. Record the usage of any concomitant medications and ongoing treatments . This should 
include the following:  
a. Documentation of the standard of care  
b. The clinical rationale for initiation of mechanical ventilation, if necessary  
c. Documentation of supportive measures for ARDS (e.g., proning, paralytics, 
etc.) 
d. Care decisions that are based on limitations of resources at the clinical site  
4. Adverse events  
5. Dose study drug  
6. At the time of discharge from the hospital, patients should be advised to use refrain 
from prolonged exposure to the sun or use at least SPF 50 on all exposed skin and 
protective clothing during prolonged sun exposure until the Day 60 adverse event 
assessment.  
8.5 Day 3, Day 9,  and Day 15  
The following additional assessment will be conducted on Day s 3, Day 9  and 15 : 
1. Serum Chemistry – (Appendix A ) 
2. Hematology – (Appendix A ) 
3. Assessment of primary and secondary endpoints (Day 15 only)  
4. Physical examination (including weight) (Day 15 only)  
5. 12 lead ECG (single) (Day 15 only)  
6. Pregnancy test (Day 15 only)  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 23 - 7. Plasma samples for pharmacokinetic assessment will be taken at baseline (prior to dosing 
on Day 15) and at 4 hours (±2 hours), 12 hours (±2 hours) after dosing on Day 15, and at 
24 hours (±2 hours) after dosing on Day 15 (prior to dosing on Day 16). (Day 15 only)  
8.6 Day 22  ± 3 days  (these assessments will also be done at Early Termination or 
Discontinuation from the study)  
The following assessments will be performed on Day 22  (± 3 days) : 
1. Vital Signs (temperature/pulse/supine blood pressure)  
2. SpO 2 
3. Physical examination  (including weight)  
4. 12-lead ECG (single)  
5. Chest X -ray or CT scan  
6. Clinical Laboratory tests  
a. Hematology ( Appendix A ) 
b. Serum chemistry (Appendix A ) 
c. Urinalysis  
7. Adverse events  
8. Record the usage of any concomitant medications and ongoing treatments.  
9. Assessment of primary and secondary endpoints  
8.7 Day 29  ± 3 days  
The following assessments will be performed at approximately Day 29  (± 3 days) : 
1. Vital Signs (temperature/pulse/supine blood pressure)  
2. SpO 2 
3. Physical examination  (including weight)  
4. 12-lead ECG (single)  
5. Chest X -ray or CT scan  
6. Clinical Laboratory tests  
a. Hematology ( Appendix A ) 
b. Serum chemistry (Appendix A ) 
c. Urinalysis  
7. Adverse events  
8. Record the usage of any concomitant medications and ongoing treatments.  
9. Assessment of primary and secondary endpoints  
10. Pregnancy test  
8.8 Follow up visits at Day 45  (± 3 days)  and Day 60  (± 3 days)  (can be conducted via 
phone/teleconference)  
1. Adverse events  
2. Assessment of primary and secondary endpoints (observational assessment)  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 24 - 8.9 Subject Stopping Rules  
If, in the opinion of the investigator, the participation in the study is or is becoming 
detrimental to the well -being of a particular subject, this issue should be discussed with the 
Medical Monitor for this study and dosing may be discontinued.  
Subjects tha t experience a Grade 4 or greater toxicity according to the Common Terminology 
Criteria for Adverse Events (CTCAE) version 4 
(https://evs.nci.nih.gov/ftp1/CTCA E/CTCAE_4.03_2010 -06-14_QuickReference_5x7.pdf)  
that is deemed to be possible, probably or definitely related to study drug will be discontinued 
from the study. Prior to discontinuation from the study, the grading of the event and causal 
relationship shoul d be discussed with the Medical Monitor for the study.  
Subjects will be discontinued from dosing if AST or ALT levels are >5 times the upp er limit 
of normal, or if AST or ALT levels are > 3 times the upper limit of normal  along with a total 
bilirubin elevat ion of >2 times the upper limit of normal . 
Subjects will be discontinued from dosing if Grade 3 diarrhea is observed.  
Subjects will be discontinued from dosing if Grade 3 neutropenia is observed.  
8.10 Early Discontinuation of Study Treatment  
A subject will be c onsidered to have completed the efficacy portion of the trial if they 
received at least 21 days of treatment with study drug  or the subject  has been discharged from 
the hospital, or the subject  has expired or the study is terminated by the sponsor .  Subjects 
may prematurely discontinue study treatment for any of the following reasons:  
1. Consent Withdrawn ( specify the reason) .   
2. Significant and unacceptable adverse event  – specify the adverse event leading to 
discontinuation  
3. Investigator decision ( specify the reason), must be approved by the Medical Monitor  
4. Non-compliance by subject with protocol requirements, must be approved by the Medical 
Monitor  
5. Lost to follow -up (record the date of last contact)  
6. Death  (specify  the following information)  
a. Date of death  
b. Death due to primary disease? Yes or no  
c. Death due to study drug? Yes or no  
d. Death due to adverse event? Yes or no  
7. Study terminated by the Sponsor  
8. Other reason (specify the reason)  should be  approved by  the Medical Monitor  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 25 - The reason for discontinuation of study treatment will be documented for each subject. 
Subjects who discontinue prematurely will not be replaced. If a subject is discontinued from 
the study, he will be asked to complete all End of Study  visit assessments  and return all study 
materials (s tudy medication and electronic device ). At the time of discontinuat ion, please fill 
out the End of Study  case report forms ( eCRF s) and subject disposition eCRF  pages.  
8.11 Adverse Events  
An adverse event (AE) is any unfavorable o r unintended change in body structure (signs) or 
body function (symptoms), abnormal laboratory result that is associated with symptoms or 
requires treatment or worsening of a pre -existing condition. This includes all such events 
regardless of the presumed relationship between the event and the study medication(s).  
Any AE that occurs after the informed consent is signed but prior to dosing on Day 1 will be 
captured as part of the medical history and will be documented on the appropriate eCRF . This 
would incl ude AEs resulting from concurrent illnesses, reactions to concomitant medications 
or progressive disease states. These AEs will be captured as part of the medical history.  
Each subject will be assessed for the development of any adverse event s. Adverse eve nts 
should be assessed at each visit to the clinic. This information should be obtained in the form 
of non -leading questions (e.g., "How are you feeling?") and from signs and symptoms 
detected during each examination, observations of the study personnel or  spontane ous reports 
from the subjects.  
Any AEs such as complaints, signs, or symptoms that occur during the course of the study or 
designated follow -up periods will be recorded on the subject's case report form  (eCRF ). This 
would include AEs resulting fro m concurrent illnesses, reactions to concomitant medications, 
or progressive disease states.  
Whenever possible, the AE will be described on the case report form using standard medical 
terminology consistent with Common Terminology Criteria for Adverse Even ts (CTCAE) 
version 4 in order to avoid the use of vague, ambiguous or colloquial expressions. The 
investigator will evaluate all adverse events as to their intensity, relation to test medication, 
outcome and action taken.  
Each AE will be evaluated for dura tion, intensity, and relationship to (or association with) the 
study treatment (or other causes). Additionally, the actions taken (e.g., reduction of dosage, 
discontinuation of study medication, administration of treatment, etc.) and the resulting 
outcome of the AE will be indicated on the case report form.  
Any subject who is withdrawn from the study due to an adverse event  will be followed until 
the outcome of the event is determined, and the investigator will prepare a written summary 
of the event and doc ument the available follow -up information on the case report form.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 26 - 8.11.1  Intensity of Adverse E vents 
The intensity of the AEs will be graded according to CTCAE version 4. For any adverse event 
that is not specifically covered in CTCAE version 4, the following criteria  should be used : 
Grade  Description  
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated  
2 Moderate; minimal, local or noninvasive intervention indicated; 
limiting age -appropriate instrumental activities of daily living  
3 Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospit alization indi cated; disabling; 
limiting self -care activities of daily living  
4 Life-threatening consequences:  urgent intervention indicated.  
5 Death related to AE  
If the intensity (Grade) changes within a day, the maximum intensity (Grade) should be 
recorded. If the intensity (Grade) changes over a longer period of time, the changes should be 
recorded as separate events (having separate onset and stop dates for each  grade).  
8.11.2  Test M edication  Causality  
The relationship (or association) of each AE to the test medication will be assessed by the 
investigator according to the following definitions:  
Unrelated:  There is no chance that the study medication caused the AE; other  conditions, 
including concurrent illnesses, progression or expression of the disease state, or a reaction to a 
concomitant medication best explain the event.  
Unlikely:  There is little chance that the study medication caused the AE; other 
conditions, inclu ding concurrent illnesses, progression or expression of the disease state, or a 
reaction to a concomitant medication best explain the event.  
Possible:  The association of the AE with the study medication is unknown; however, the 
AE is not clearly due to ano ther condition.  
Probable:  A reasonable temporal association exists between the AE and treatment 
administration and, based on the investigator's clinical experience, the association of the AE 
with the study treatment seems likely.  
Definite:  The association of the AE with the study medication has a direct relationship.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 27 - For the purpose of safety analyses, all AEs which are classified as "Possible," "Probable" or 
“Definite” will be considered treatment -related events.  
8.11.3  Serious Adverse E vents 
A serious adverse ev ent (SAE)  is defined as any experience that suggests a significant 
clinical hazard, contraindication, side effect, or precaution. This includes any event which:  
• Results in death.  
• Is life -threatening.  
• Requires inpatient hospitalization or causes prolongation of existing hospitalization  
• Results in persistent or significant disability/incapacity.  
• Results in congenital abnormality/birth defect.  
• Requires intervention to prevent permanent impairment or damage  
 
An SAE also may include other events, based on medical judgment, which jeopardize the 
subject and require medical or surgical intervention to prevent one of the outcomes listed 
above.  
Any SAE, including death due to any cause, which occurs during the study or within 60 days 
following i nitiation of dosing on study medication, whether or not related to the study 
medication, must be reported immediately via telephone (within 24  hours) to Veru Inc. Drug 
Safety . 
In addition, the investigator must immediately complete a Serious Adverse Event eCRF  report 
form and electronically submit the form.  The investigator will promptly notify the 
Institutional Review Board  (IRB). 
If additional information regarding a previously submitted SAE is obtained, a follow -up SAE  
eCRF  report should be completed and  submitted  as indicated above.  Supporting source 
documen tation should be provided to Worldwide Clinical Trials Drug Safety  at the contact 
information below.  
 Worldwide Clinical Drug Safety Contact Information : 
Fax number: 1-866-387-5539  
  
E-mail: drugsafety@worldwide.com  
  
Worldwide Clinical Trials  Medical Monitor:  
 
Noor Khaskhely, MD, PhD  Sr. Medical Director, Medical Affairs Worldwide 
Clinical Trials  
Office +1 610 632 8151Mobile +1 919 324 4351  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 28 -  noor.khaskhely@worldwide.com  
 
8.11.4  Initial Reports  
SAEs will be collected from the time of first stud y drug administration through 60 days after 
first study drug administration .  SAEs and events of clinical interest must be reported to the 
Sponsor (or designee ) within 24 hours of the knowledge of the occurre nce.  
In the event an SAE is observed or reported, the SAE report will be completed as thoroughly 
as possible including all available details about the event and the signature of the Investigator. 
If the Inv estigator does not have all information about an SAE, the Investigator will not wait 
to receive additional information before notifying the Sponsor of the event and completing the 
form. The form will be updated when additional information is received.  
8.11.5  Precautions  
Adverse event s should be treated in accordance with standard medical practice. During the 
course of the study, the overall safety, and tolerability  of all study treatments will be reviewed 
by the sponsor and the investigator.  
8.11.6  Reporting of Adverse Events Associated with Study Drug Overdose, Misuse, 
Abuse or Medication Error  
AEs associated with study drug overdose, misuse, abuse, and medication error refer to AEs 
associated with uses of the study drug outside of that specified by the protocol . Overdose, 
misuse, abuse, and medication error are defined as follows:  
Overdose: Accidental or intentional use of the study drug in an amount higher than the 
protocol -defined dose  
Misuse:  Intentional and inappropriate use of study drug not in accordance with the protocol  
Abuse: Sporadic or persistent intentional excessive use of study drug accompanied by harmful 
physical or psychological effects  
Medication error: Any unintentional event that causes or leads to inappropriate study drug use 
or su bject harm while the study drug is in the control of site personnel or the subject.  
All AEs associated with overdose, misuse, abuse, or medication error should be captured on 
the Adverse Event eCRF and also reported using the procedures detailed in Reporti ng of 
SAEs even if the AEs do not meet serious criteria. Abuse is always to be captured as an AE. If 
the AE associated with an overdose, misuse, abuse, or medication error does not meet serious 
criteria, it must still be reported using the SAE form and in an expedited manner but should be 
noted as non -serious on the SAE form and the Adverse Event eCRF.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 29 - 8.12 Concomitant  Medications  and Concomitant Therapies  
Any medication  (including OTC medications)  taken by a subject within 30 days prior to the 
Screening Visit a nd during the course of the study and the reason for use of the medication 
will be recorded on the eCRF . Upon entering the study, each subject will be instructed to 
report the use of any medication (including OTC medications) to the investigator.  
Any radia tion therapy (linear beam or seeds) taken by the subject within 30 days prior to the 
Screening Visit and during the course of the study, including type of treatment, and duration 
of the treatment will be recorded on the eCRF . 
8.13 Prohibited  Medications  
The fol lowing medications are prohibited  with the appropriate washout period, if any, for 
each prohibited medication:  
• Retroviral /antiretroviral medications , except for remdesivir   
• Any experimental drug/clinical trial , except for remdesivir  and convalescent plasma  
 
8.14 Withdrawal  of Subjects  
All subjects reserve the right to withdraw from the study at any time. The investigator will 
encourage all subjects who decide to withdraw from the study to complete all evaluations 
which may be necessary to assure that the subject  is free of untoward effects and to seek 
appropriate follow -up for any continuing problems.  
 
a. Any subject who  withdrawals consent will be withdrawn from the study . 
e. Any subject who is lost -to-follow -up will be withdrawn from the study.  
The investigator will withdraw any subject from the study if, in the investigator's opinion, it is 
not in the subject's best interest to continue . 
The date the subject is withdrawn from the study and the reason for discontinuation will be 
recorded on the case report form. When a subject fails to return for scheduled study visits, the 
investigator will make a reasonable effort to contact the subject and determine why the 
subject failed to return. This information will be documented on the study records. Whe n a 
subject is withdrawn from the study (regardless of the reason), all evaluations required at the 
final s tudy visit should be performed.  
9.0 STATISTICAL ANALYSIS  
9.1 Sample  Size Calculation  
In the Phase 2, there are no power calculations done to determine the sa mple size. The Phase 
2 study is intended as a proof -of-concept study only.   
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 30 - 9.2 Populations  
Intent -to-Treat (ITT) population:  All enrolled subjects who have taken at least one dose of 
study drug.  The ITT population will be used as the safety population.  
Modifi ed Intent -to-treat (MITT) population:  All enrolled subjects who have taken at least 
7 doses of study drug . 
9.3 Efficacy Analyses  
A statistical analysis plan will be written for this Phase 2 clinical study. A detailed description 
of the analyses that will be conducted will be included in that document.  
9.3.1 Primary Endpoint  
The primary endpoint for the study  will be the proportion of subjects that are alive without 
respiratory failure at Day 29. Respiratory failure is defined endotracheal intubation and 
mechanical ventilation, extracorporeal membrane oxygenation, high -flow nasal cannula 
oxygen delivery, noninvasive positive pressure ventilation, clinical diagnosis of respiratory 
failure with initiation of none of these measures only when clinical decision making is driven 
solely by resource limitation.  
This analysis will compare the percentage of subjects that are alive without respiratory failure 
on Day 22 (responder). The percentage of subjects that meet these criteria in each of the two 
treatment groups will be su mmarized and compared observationally and statistically.  
The number and percentage of responders will be summarized by treatment group. 
Responders will be analyzed using a logistic regression model. This model will include 
treatment as a factor and study s ite and WHO Ordinal Scale for Clinical Improvement at 
baseline as a covariates. Odds ratios, standard errors, 95% confidence intervals and p -values 
for the treatment difference will be presented.  
The primary analysis will be performed on the ITT population . Subjects for whom respiratory 
failure and/or vital status at Day 29 cannot be established will be excluded from the analysis, 
noting that the number of such subjects is expected to be minimal. A sensitivity analysis will 
be performed treating these subje cts as non -responders. A further sensitivity analysis also be 
performed on the mITT population.  
9.4 Secondary Analyses  
Full details for the handling of missing data, and consideration of subjects that die during the 
study for those endpoints that do not direct ly incorporate death, will be included in the 
Statistical Analysis Plan.  
9.4.1 Secondary Endpoints  
9.4.1.1  Mean change from baseline in WHO Ordinal Scale for Clinical Improvement at 
Day 15, Day 22 and Day 29  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 31 - The mean change in WHO Ordinal Scale for Clinical Improvement from baseline to Day 22 
and from baseline to Day 29 will be assessed.  
The worst category recorded on Day -1 will be baseline and the worst category recorded on 
Day 22 and Day 29 of the study wi ll be used in this analysis.  
Descriptive statistics (n, mean, standard deviation, median, minimum and maximum) will be 
summarized for absolute values, and change from baseline  by treatment group and visit.  
Change from baseline will be analyzed using mixe d model for repeated measures (MMRM) 
including treatment, visit and treatment -by-visit interaction as fixed effects and study site and 
WHO Ordinal Scale for Clinical Improvement at baseline as covariate. The resulting F -tests 
will be based on Kenward -Roger ’s adjusted degrees of freedom. Least squares means, 
standard errors, 95% confidence intervals and p -values for treatments and treatment 
differences at each visit will be presented.  
9.4.1.2  Proportion of subjects that are Grade 5, 6, 7, or 8  on the WHO Ordinal Sca le for 
Clinical Improvement at Day 15 , Day 22, and Day 29  
Proportion of subjects that are Grade 5, 6, 7, or 8 on the WHO Ordinal Scale for Clinical 
Improvement at Day 15, Day 22, and Day 29 will be assessed. This analysis will compare the 
percentage of sub jects that have NOT progressed to a WHO Ordinal Scale for Clinical 
Improvement score of 5, 6, 7, or 8  (responder)  on Day 15, Day 22 or Day 29. The worst 
category on each day of the study will be used in this analysis. The percentage of subjects that 
meet t hese criteria in each of the two treatment groups will be summarized and compared 
observationally and statistically.  
This endpoint will be analyzed using the same methodology as for the primary endpoint.   
9.4.1.3  Proportion of subject s with normalization of fever and oxygen saturation 
through Day 15 , Day 22, and Day 29 .  
The percentage of subject s with normalization of fever and oxygen saturation through Day 15 , 
Day 22  and Day 29 (inclusive)  will be summarized. A subject will be considered as  a 
treatment success if fever normalization maintained for at least 24 hours AND peripheral 
capillary oxygen saturation (SpO 2) >94% sustained for 24 hours is observed.  
This analysis will compare the percentage of subjects that meet the composite endpoint o f 
fever normalization maintained for at least 24 hours AND peripheral capillary oxygen 
saturation (SpO 2) >94% sustained for 24 hours is observed  (responder) at Day 15, Day 22, 
and Day 29 . The percentage of subjects that meet these criteria in each of the two treatment 
groups will be summarized and compared observationally and statistically.  
This endpoint will be analyzed using the same methodology as for the primary endpoint.  
9.4.1.4  Days on mechanical ventilation  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 32 - Days on mechanical ventilation  will be summarized using descriptive statistics (n, mean, 
standard deviation, median, minimum and maximum) by treatment group. Treatment 
comparison will be based on analysis of covariance (ANCOVA) model including treatment as 
a factor and study site and WHO Ordinal Scale for  Clinical Improvement at baseline as 
covariates. T reatment difference, standard error, 95% confidence interval and p -value will be 
presented . 
9.4.1.5  All-cause mortality at Day 15 , Day 22, and Day 29  
The number and percentage for all -cause mortality will be summar ized by treatment group 
and timepoint.  
This endpoint will be analyzed using the same methodology as for the primary endpoint.  
All-cause mortality  will be analyzed by comparing the survivor functions between treatment 
arms using Kaplan -Meier methodology. Proportion of mortality and 95% confidence intervals 
at Day 15, Day 22 and Day 29 will  be reported. Log -rank test will be performed to test the 
homogeneity of survival curves between the treatment groups. Cox’s proportional hazards 
model will be fitted to assess the significance of the differences between treatment arms. 
Model will include term for treatment and WHO Ordinal Scale for Clinical Improve ment at 
baseline as covariate.  
9.4.1.6  Proportion of patients alive and free of respiratory failure at Day 15 , and Day 22 
The percentage of subject s alive and free of respiratory failure  through Day 15 , and Day 22 
(inclusive)  will be summarized.  
This analysis will compare the percentage of subjects that are alive and free of respiratory 
failure (responder) at Day 15, and Day 22. The percentage of subjects that meet these criteria 
in each of the three treatment groups will be summarized and compare d observationally and 
statistically.  
This endpoint will be analyzed using the same methodology as for the primary endpoint.  
9.4.1.7  Proportion of patients alive and discharged from the ICU at Day 15 , Day 22, and 
Day 29  
The percentage of subject s alive and discharg ed from the ICU  through Day 15 , Day 22  and 
Day 29 (inclusive)  will be summarized.  
This analysis will compare the percentage of subjects that are alive and discharged from the 
ICU (responder) at Day 15, Day 22, and Day 29. The percentage of subjects that me et these 
criteria in each of the two treatment groups will be summarized and compared observationally 
and statistically.  
This endpoint will be analyzed using the same methodology as for the primary endpoint.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 33 - 9.4.1.8  Proportion of patients alive and discharged from  hospital at Day 15 , Day 22, and 
Day 29  
The percentage of subject s alive and discharged from the hospital  through Day 15 , Day 22  
and Day 29 (inclusive)  will be summarized.  
This analysis will compare the percentage of subjects that are alive and discharged from the 
hospital (responder) at Day 15, Day 22, and Day 29. The percentage of subjects that meet 
these criteria in each of the two treatment groups will be summarized and compared 
observationally and statistically.  
This endpoint will be analyzed using the  same methodology as for the primary endpoint.  
9.4.1.9  Days in ICU  
Days in ICU will be summarized using descriptive statistics (n, mean, standard deviation, 
median, minimum and maximum) by treatment group.  
Days in ICU will be analyzed using the same methodology as for Days on Mechanical 
Ventilation (section 9.4.1.4).  
9.4.1.10  Days in hospital  
Days in hospital  will be summarized using descriptive statistics (n, mean, standard deviation, 
median, minimum and maximum) by treatment group.  
Days in hospital will be analyzed using the same methodology as for Days on Mechanical 
Ventilation (section 9.4.1.4).  
9.4.1.11  Proportion of subjects on mechanical ventilation at  Day 1 5, Day 22, and Day 29  
The percentage of subject s on mechanical ventilation  through Day 15 , Day 22  and Day 29 
(inclusive)  will be summarized.  
This analysis will compare the percentage of subjects that are NOT on mechanical ventilation 
(responder) at Day 15, Day 22, and Day 29. The percentage of subjects that meet these criteria 
in each of the two treatment grou ps will be summarized and compared observationally and 
statistically.  
This endpoint will be analyzed using the same methodology as for the primary endpoint.  
9.4.1.12  Mean change from baseline in C -reactive protein at Day 9  
The mean change in C -reactive protein fro m baseline to Day 9 will be assessed.  
Descriptive statistics (n, mean, standard deviation, median, minimum and maximum) will be 
summarized for absolute values, and change from baseline  by treatment group.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 34 - Change from baseline will be analyzed using mixed model for repeated measures (MMRM) 
including treatment, visit and treatment -by-visit interaction as fixed effects and study site and 
C-reactive protein level  at baseline as covariate. The resulting F -tests w ill be based on 
Kenward -Roger’s adjusted degrees of freedom. Least squares means, standard errors, 95% 
confidence intervals and p -values for treatments and treatment differences at each visit will be 
presented.  
9.5 Interim Analysis  
Due to the unexpectedly slow enrollment into this study, Veru is conducting a limited interim 
analysis after 24 subjects have been treated for 15 days or have discontinued from the study.  
The interim analysis will focus on the fol lowing endpoints:  
1. Proportion of subjects alive wit hout respiratory failure at Day 15  
This will analyzed similar to the outline in Section 9.4.1.6.  
2. Days in ICU up to Day 15  
This will be analyzed similar to the outline in Section 9.4. 1.9. However, only to Day 
15. The highest possible number of days in the I CU is 15 days.  
3. Days in hospital up to Day 15  
This will be analyzed similar to  the outline in Section 9.4.1.10. However, only to Day 
15. The highest possible number of days in the hospital is 15 days.  
4. Exogenous oxygen use (shift table from baseline to Day 3, 9 and 15) 
This will be three shift tables (increase, decrease, no change) f rom baseline to Day 3, 
baseline to Day 9, and baseline to Day 15.  
9.6 Pharmacokinetic Analysis  
The pharmacokinetics of VERU -111 will be assessed on Day 1 5. Plasma samples for 
pharmacokinetic assessment will be taken at baseline (prior to dosing on Day 15) and at 4 
hours (±2 hours), 12 hours (±2 hours) after dosing on Day 15, and at 24 hours (±2 hours) after 
dosing on Day 15 (prior to dosing on Day 16) . 
AUC 0-t, Cmax, Tmax, kel, Cl/F, T½, and V d/F will be estimated  through standard methodology  
with this limited sampling schedule .  
The limited sampling schedule is used due to limitations on study personnel entering the 
patient’s room during the day.  If the sample is missed due to restrictions in entering the room, 
then this sample will be listed as missing.  
The blood sample should be collected in a 6 mL K 2EDTA blood collection tube at each 
collection time.  
Immediately after collection, the tube will be gently inverted several times to mix the 
anticoagulant with the b lood sample. The blood sample should be kept at room temperature 
until processed. The blood samples should be processed within 20 minutes after collection. 
The plasma fraction will be separated by placing the collection tube into a centrifuge for 10 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 35 - minute s at 1,500 x g (at room temperature). The plasma fraction will be withdrawn by pipette 
and divided into two polypropylene freezing tubes (with each tube receiving approximately 
equal aliquots). All plasma samples will be placed into a freezer at -20oC (or below) within 1 
hour after collection. (NOTE: A flash freezing in dry ice or liquid nitrogen is NOT required 
under this protocol but may be used.)  
9.6.1 Plasma Sample Labels  
The plasma freezing tube labels will contain the following information:  
• Subject Number  
• Study Number  
• Site Number  
• Dosing time (hour and minute)  
• Sample time (hour and minute)  
• Aliquot Number: Aliquot A or B  
• Species and Matrix: Human Plasma  
• Sample Sequence Number  
• Barcode Number  
Labels will be fixed to freezing tubes in a manner that will p revent the label from becoming 
detached after freezing.  
All plasma samples will be stored frozen ( -20°C or below). Details of the method validation 
and sample analysis will be included with the final report.  
9.7 Safety Analysis  
The frequency of adverse events  (AEs) will be tabulated by MedDRA term and system organ 
class. The incidence of AEs and the maximum intensity and frequency of AEs will be 
summarized. A new  onset AE is defined as an AE that was not present prior to treatment with 
study medication but app eared following treatment or was present at treatment initiation but 
worsened during treatment. An AE that was present at treatment initiation but resolved and 
then reappeared while the subject  was on treatment is a new -onset AE (regardless of the 
intensity of the AE when the treatment was initiated).  
All laboratory  results, vital sign measurements, and other safety variables will be summarized 
using appropriate descriptive statistics. Changes f rom baseline will be computed and will be 
summarized using appropriate descriptive statistics.  
9.7.1 Data Safety Monitoring Board  
A Data Safety Monitoring Board will review the unblinded safety data from this  Phase 2 
study , including all SAEs,  every 2 weeks , or more often if the safety observations . 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 36 - The recruitment of this Phase 2 study is expected to be completed within 4 weeks of first 
patient, first dose. Therefore, f rom first patient, first dose, to last patient, last dose is expected 
to be  <50 days.  
10.0 ADMINIST RATION PROCEDURES  
10.1 Study Conduct and Compliance  
The study will be conducted in accordance with the Code of Federal Regulations (21 CFR 
parts 50, 54, 56, 312, and 314), which originates from the ethical principles laid down in the 
Declaration of Helsinki. Go od Clinical Practices (GCPs) and the policies and procedures of 
the Sponsor and/or its authorized representative will also be followed. This clinical trial will 
be overseen and managed by a contract research organization (CRO) and the Sponsor. The 
CRO will  be responsible for data management, data handling, statistical analysis, quality 
assurance and the final study report. The Sponsor will be responsible for project management 
of the CRO and clinical monitoring.  
Sponsor Emergency Contact Info:  
K. Gary Barnette , Ph.D.  
Chief Scientific Officer  
Veru Inc.  
Cell: 9 19-426-3611  
 
Before initiating a trial, the Investigator/ Institution should have written and dated 
approval/favorable opinion from the Independent Ethics Committee (IEC)/IRB for the trial 
protocol/amendment(s), written informed consent form, any consent form updates, subject 
recruitment procedures (e.g. , advertisements), any written information to be provided to 
subjects and a statement from the IEC/IRB that they comply with GCP requirement s. The 
IEC/IRB approval must identify the protocol version as well as the documents reviewed.  
After IEC/IRB approval, changes will require a formal amendment. Once the study has 
started, amendments should be made only in exceptional circumstances. Changes that do not 
affect subject safety or data integrity are classified as administrative changes and generally do 
not require ethical approval. If ethically relevant aspects are concerned, the IEC/IRB must be 
informed and, if necessary, approval sought prior t o implementation. Ethical approval on 
administrative changes will be obtained if required by local/site IEC/IRB.  
10.2 Informed Consent  
Prior to study entry, the Investigator, or a person designated by the Investigator, will explain 
the nature, purpose, benefits  and risks of participation in the study to each subject, subject’s 
legally acceptable representative or impartial witness. Written informed consent must be 
obtained prior to the subject entering  the study (before initiation of any study -related 
procedure and administration of the investigational medicinal product ( IMP). Sufficient time 
will be allowed to discuss any q uestions raised by the subject.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 37 - The Sponsor will provide a sample informed consent form. The final version -controlled form 
must be agreed to by the Sponsor and the IEC/IRB and must contain all elements included in 
the sample form, in language readily understood by the subject. Each subject’s original 
consent form, personally signed and dated by the subject or by the subject’s legally acceptable  
representative, and by the person who conducted the informed consent discussion, will be 
retained by the Investigator. The Investigator will supply all enrolled subjects with a copy of 
their signed informed consent.  
The consent form may need to be revised  during the trial should important new information 
become available that may be relevant to the safety of the subject or as a result of protocol 
amendments. In this instance approval should always be given by the IEC/IRB. It is the 
Investigator’s responsib ility to ensure that all subjects subsequently entered into the study and 
those currently in the study sign the amended form. This is documented in the same way as 
previously described. Subjects who have completed the study should be informed of any new 
information that may impact on their welfare/wellbeing.  
The Investigator should, with the consent of the subject, inform the subject’s primary 
physician about their participation in the clinical trial.  
10.3 Protocol Amendments  
In the event that an amendment to this protocol is required, it  will be classified into one of the 
following three categories:  
• Non-Substantial Amendments  are those that are not considered ‘substantial’ (e.g. , 
administrative changes) and as such only need to be notified to the IECs/IRBs or 
Competent Authorities (CA) for information purposes.  
• Substantial Amendments  are those considered ‘substantial’ to the conduct of the clinical 
trial where they are likely to have a significant impact on:  
- the safety or physical or mental integrity of the subjects;  
- the scientific value of the trial;  
- the conduct or management of the trial; or  
- the quality or safety of the IMP used in the trial.  
Substantial amendments must b e notified to the IECs/IRBs and CA. Prior to 
implementation, documented approval must be received from the IECs/IRBs. In the case 
of the CA in the EU member states, approval or ‘favorable opinion’ can be assumed if the 
CA has raised no grounds for non -acceptance during an allocated time period (to be 
confirmed with the Sponsor’s Regulatory Affairs (RA) representative) following 
acknowledgment of receipt of a valid application to make a substantial amendment.  
• Urgent Amendments  are those that require urgent s afety measures to protect the trial 
subjects from immediate hazard and as such may be implemented immediately by the 
Sponsor with subsequent IECs/IRBs and CA notification, forthwith.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 38 - 10.4 Protocol Deviations  
It is the responsibility of the Investigator and Spon sor to ensure compliance with the study 
protocol. When the protocol is not followed, it can put the safety of study subjects at risk as 
well as jeopardize the accuracy and reliability of the study results which could lead to a 
rejection of the data by regu latory authorities.  
All identified deviations from the protocol must be documented and reported to the Sponsor 
using the appropriate electronic form to be supplied by the Sponsor . Deviations will be 
categorized into minor d eviations or major deviations; d efinitions and examples of deviations 
will be provided by the Sponsor . The Sponsor will be reviewing all deviations on an ongoing 
basis.  
10.5 Data Handling and Recordkeeping  
10.5.1  Data Handling  
Data will be recorded at the site on the eCRF  and reviewed by the clinical research associate 
(CRA) during monitoring visits. The CRA will verify data recorded in the EDC system with 
source documents. All corrections or changes made to any study data must be appropriately 
tracked in an audit trail in  the EDC system. An eCRF  will be considered complete when all 
missing, incorrect, and/or inconsistent data has been accounted for and electronically signed 
by the Investigator or assignee.  
Data will be processed using a validated computer system conforming  to regulatory 
requirements.  
10.5.2  Data Entry  
Data must be recorded using the EDC system as the study is in progress. All site personnel 
must log into the system using their secure username and password in order to enter, review, 
or correct study data. These pro cedures must comply with Title 21 of the Code of Federal 
Regulations (21  CFR Part 11) and other appropriate international regulations. All passwords 
will be strictly confidential.  
10.5.3  Medical Information Coding  
For medical information, the following thesauri w ill be used:  
• Latest version of MedDRA (version 18.1 or higher) for medical history and AEs, and  
• World Health Organization Drug Dictionary Enhanced (Sept. 2015 or later) for prior and 
concomitant medications.  
10.5.4  Data Validation  
Validation checks programmed within the EDC system, as well as supplemental validation 
performed via review of the data, will be applied to the data in order to ensure accurate, 
consistent, and reliable data. Data identified as erroneous, or data that are missing, will be 
referred to the site for resolution through data queries.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 39 - The eCRF s must be reviewed and electronically signed by the Investigator in order to be 
considered complete.  
10.5.5  Record Keeping  
Records of subjects, source documents, monitoring visit l ogs, eCRF s, inventory of study 
drugs, regulatory documents, and other Sponsor correspondence pertaining to the study must 
be kept in the appropriate study files at the site. Source data is defined as all information in 
original records and certified copies  of original records of clinical findings, observations, or 
other activities in a clinical study necessary for the evaluation and reconstruction of the 
clinical study. Source data are contained in source documents (original records or certified 
copies). Th ese records will be retained in a secure file for the period as set forth in the Clinical 
Study Agreement. Prior to transfer or destruction of these records, the Sponsor must be 
notified in writing and be given the opportunity to further store such records .  
10.6 Data Quality  
Monitored eCRF s transferred from the investigational site to the assigned Data Management 
group will be reviewed (secondary monitoring) for completeness, consistency, legibility and 
protocol com pliance.  
Reasons should be given on the releva nt eCRF  for any missing data and other protocol 
deviations. Any electronic queries and items not adequately explained will require additional 
electronic manual queries to be raised to the Investigator by the monitor for 
clarification/correction. The Invest igator must ensure that queries are dealt with promptly. All 
data changes and clarifications can be viewed in the audit trail function of the eCRF . 
Clinical site personnel must make themselves available for any potential audit by the Sponsor 
or Sponsor rep resentative and regulatory authorities, such as, but not limited to , United States 
Food and Drug Administration. The clinical site personnel must be completely responsive and 
cooperative during these audits.  
10.7 Regulatory Approval  
As required by local regulat ions, the Sponsor’s Regulatory Affairs group will ensure all legal 
regulatory aspects are covered , and obtain approval of the appropriate regulatory bodies, prior 
to study initiation in regions where an approval is required.  
10.8 Publication Policy  
The Sponsor encourages acknowledgement of all individuals/organizations involved in the 
funding or conduct of the study, including medical writers or statisticians subject to the 
consent of each individual and entity concerned, including acknowledgement of the Sponsor . 
The results of this study may be published or communicated to scientific meetings by the 
Investigators involv ed in the study. For multicenter  studies, a plan for scientific publication 
and presentation of the results may be agreed and implemented by the study Investigators or a 
Steering Committee. The Sponsor requires that reasonable opportunity be given to review the 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 40 - content and conclusions of any abstract, presentation, or paper before the material is 
submitted for publication or communicated. This cond ition also applies to any amendments 
that are subsequently requested by referees or journal editors. The Sponsor will undertake to 
comment on the draft documents within the time period agreed in the contractual 
arrangements, including clinical trial agreem ents, governing the relationship between the 
Sponsor and authors (or the author’s institution). Requested amendments will be incorporated 
by the author, provided they do not alter the scientific value of the material.  
If patentability would be adversely affected by publication, this will be delayed until (i)  a 
patent application is filed for the content of the publication in accordance with applicable 
provisions of the clinical trial agreement concerned, (ii)  the Sponsor consents to the 
publicat ion, or  (iii) the time period as may be agreed in the contractual arrangements, 
including clinical trial agreements, governing the relationship between the Sponsor and 
authors (or authors’ institution) after receipt of the proposed publication by the Spons or, 
whichever of ( i), (ii) or (iii) occurs first.  
The author undertakes to reasonably consider the Sponsor's request for delay to the proposed 
publication should the Sponsor reasonably deem premature to publish the results obtained at 
the then stage of the  study.  
10.9 Clinical Study Report  
A final clinical study report will be prepared according to the ICH guideline on structure and 
contents of clinical study reports. A final clinical study report will be prepared where any 
subject has signed informed consent, r egardless of whether the trial is completed or 
prematurely terminated. Where appropriate an abbreviated report may be prepared. The CSR 
will be in compliance with any applicable regulatory requirements, national laws in force and 
will be in English.  
10.10  Contra ctual and Financial Details  
The Investigator (and/or, as appropriate, the hospital/institution authorized representative) and 
the Sponsor will sign a clinical study agreement prior to the start of the study, outlining 
overall Sponsor and Investigator respo nsibilities in relation to the study. Financial 
remuneration will cover the cost per included subject, based on the calculated costs of 
performing the study assessments and other activities in accordance with the protocol, and the 
specified terms of paymen t will be described in the contract. The contract should describe 
whether costs for pharmacy, laboratory and other protocol -required services are being paid 
directly or indirectly.  
10.11  Insurance  and Indemnity  
The Sponsor will obtain Product Liability insurance  providing coverage relating to the clinical 
study and subjects participating therein.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 41 - 11.0 REFERENCES   
Biswas K et al. Effect of microtubule disruption on neuronal spread and replication of 
demyelinating and nondemyelinating strains of mouse hepatitis virus in vitro. J Virol 88:3 -43-
3047, 2014.  
Burkard C et al. Coronavirus cell entry occurs through the endo -/lysosomal pathway in a 
proteolysis -dependent manner. PLOS Pathogens 10:e1004502, 2014.  
Cascella M. et al. Features, evaluation, and treatment coronavirus (COVID -19) StatPearls 
2020  www.ncbi.nlm .nih.gov/ books/NBK554776 . 
Chen J et al. Discovery of novel 2 -aryl-4-benzoyl -imidazole (ABI -III) analogues targeting 
tubulin polymerization as antiproliferative agents.  J Med Chem 55:7285 -7289, 2012.  
Cooper GM. The Cell: A Molecular Approach.2nd edition. S underland(MA): Sinauer 
Associates 2000. Microtubules. https://www.ncbi.nlm.nih.gov/books/NBK9932 . 
Criglar JM et al. A novel form of rotavirus NSP2 and phosphorylation -dependent NSP2 -
NPS5 interactio ns are associated with viroplasm assembly. J Virol 88:786 -798, 2014.  
Dohner K et al. Viral stop -and-go along microtubules: taking a ride with dynein and kinesins. 
Trends in Microbiology 13:320 -327, 2005.  
Eichwald C et al. Rotavirus viroplasm fusion and per inuclear localization are dynamic 
processes requiring stabilized microtubules. PLoS One 7:e47947, 2012.  
Fung S et al. Human Coronavirus: host -pathogen interaction. Annu Rev Microbiol 73:529 -57, 
2019.  
Gorbalenya AE et al. The species severe acute respirator y syndrome -related coronavirus: 
classifying 2019 -nCoV and naming it SARS -CoV -2.  Nat Microbiol 2020.  
Han X et al. Influenza virus A/Beijing/501/2009 (H1N1) interacts with beta tubulin and 
induces disruption of the microtubule network and apoptosis on A549 cells.  PLoS One:7, 
e48340, 2012.  
Hara Y et al. Propagation of swine hemagglutinating encelphalomyelitis virus and 
pseudorabies virus in dorsal root ganglia cells. J Vet Med Sci 71:595 -601, 2009.  
Heald R et al. Microtubule dynamics. J Cell Sci 115, 3 -4, 200 2. 
Knoops K et al. Integrity of the early secretory pathway promotes, but is not required for, 
severe acute respiratory syndrome coronavirus RNA synthesis and virus -induced remodeling 
of endoplasmic reticulum membranes. J Virol 84:833 -846, 2010.  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 42 - Li CM et a l. Orally bioavailable tubulin antagonists for paclitaxel -refractory cancer. Pharm 
Res 29:3053 -3063, 2012.  
Lv et al. Porcine hemagglutinating encephalomyelitis virus activation of the integrin a5b1 -
FAK -cofilin pathway causes cytoskeleton rearrangement to p romote its invasion of N2a cells. 
J Virol 93:1 -19, 2019.  
Milewski A et al. Entry of human coronavirus NL63 into the cell. J Virology 92:e01933 -17, 
2018.  
Naghavi MH et al. Microtubule regulation and function during virus infection. J Virol 
91:e00538 -17, 201 7. 
Oostra M et al. Localization and membrane topology of coronavirus nonstructural protein . 4: 
involvement of the early secretory pathway in replication. J Virol 81:12323 -12336, 2007.  
Ren et al. Genetic drift of human coronavirus OC43 spike gene during adaptive evolution. 
Scientific Reports 5:11451, 2015.  
Rudiger AT et al. Tubulins interact with porcine and human S proteins of the genus 
alphacoronavirus  and support successful assembly and release of infectious viral particles. 
Virology 497:185 -197, 2016.  
Simpson C et al. Microtubules in influenza virus entry and egress. Viruses 12:117, 2020.  
Slobodnick A et al. Update on colchicine, 2017. Rheumatology 5 7:i4-i11, 2018.  
Suomalainen M et al. Adenovrius -activated PKA and p38/MAPK pathways boost 
microtubule -mediated nuclear targeting of virus.  EMBO J 20:1310 -1319, 2001.  
Verweyen E et al. Synergistic signaling of TLR and IFN  alpha/beta facilitates escape of I L-18 
expression from endotoxin tolerance. American J Resp and Critical Care Medicine 201:526 -
539, 2020.  
Ward B. The taking of the cytoskeleton one two three: How viruses utilize the cytoskeleton 
during egress. Virology 411:244 -250, 2011.  
 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020
  - 43 - 12.0 APPENDICES  
12.1 Appen dix A: Clinical Laboratory Tests  (local  laboratory)  
Hematology:  Serum Chemistry:  
Hemoglobin  Sodium  
Hematocrit  Potassium  
Red Blood Cell Count  Chloride  
White Blood Cell Count  Bicarbonate  
White Blood Cell Differential  BUN  
Platelet Count  Creatinine  
Reticulocyte Count  Calcium  
Cardiac Trop onin Phosphorus  
 Total Protein  
Urinalysis:  Albumin  
pH Total Bilirubin  
Specific Gravity  SGOT  (ALT)  
Protein  SGPT  (AST)  
Glucose  Alkaline phosphatase  
Leucocytes  LDH  
Nitrates  GGT  
Ketones  Glucose  
Blood  Ferritin  
Microscopic Examination (only if urinalysis results are 
abnormal)  D-dimer  
 C-reactive protein  
 
  
 
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020   - 44 - 12.2 Appendix B:  Schedule of Study Evaluations  
Day Screena Day 1  Days 2 -21 Days 3, 9, & 15  Day 16  Days 22d and 29   Days 45 and 60  
Informed Consent  and 
HIPAA  X       
Medical History  X X      
Assessment of Eligibility  X X      
Physical Exam  X X  Xf  X  
Vital signs  X X X   X  
Pregnancy test (female 
subjects only)  X  Xf   Xg  
12-lead ECG  (single)  X   Xf  X  
Chest X -ray or CT   X    X  
Clinical Laboratory Tests         
Hematology  X X  X  X  
Urinalysis  X X    X  
Serum Chemistry  X X  X  X  
Temperature/SpO 2 X X Xe   X  
Dosingb,c  X X     
Pharmacokinetic assessment     Xh, f Xh   
Assessment of primary and 
secondary efficacy endpoints     Xf  X X 
Assessment of conmeds  X X X   X  
Assessment of AEs   X X   X X 
a Screening evaluations are to be conducted within 2 days prior to Day 1.  
b Subjects will be treated for 21 days OR until discharged from hospital  
c Subjects can be discontinued if they are not responding to therapy  
d Early termination assessments the same as Day 22 assessments  
e Temperature and SpO 2 will be taken every 12 hours on these days  
f Day 15 only  
g Day 29 only  
h Plasma samples for pharmacokinetic assessment will be taken at baseline (prior to dosing on Day 15) and at 4 hours (±2 hours) , 12 hours (±2 hours) after dosing on Day 15, and at 24 hours (±2 hours) after dosing on 
Day 15 (prior to dosing on Day 16).  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020  
 - 45 -  
PROTOCOL SIGNATURE PAGE  
 
Protocol Number:  V0211901  
Protocol  Date:  FINAL  Amendment 6 (Version 7)/ 25 September  2020 
  
Protocol Title:  Randomized , Placebo -Controlled , Phase 2 S tudy of VERU -111 for 
the Treatment of Severe Acute Respiratory Syndrome Coronavirus 
2 (SARS -CoV -2) in Patients at High Risk for Acute Respiratory 
Distress Syndrome (ARDS).  
 
 
SIGNATURE:  
   
Sponsor   Date  
.  
Name and Title of Sponsor Representative   
 
 
This signature of the Sponsor Representative constitutes approval of this protocol.  
  
Veru Inc  CONFIDENT IAL 
Protocol V0211901  – FINAL Version 7.0 
FINAL: Amendment 6 (Version 7) 25 September  2020  
 - 46 -  
PRINCIPAL INVESTIGATOR SIGNATURE PAGE  
 
Protocol Number:  V0211901  
Protocol Title:  Randomized , Placebo -Controlled , Phase 2 S tudy of VERU -111 for 
the Treatment of Severe Acute Respiratory Syndrome Coronavirus 
2 (SARS -CoV -2) in Patients at High Risk for Acute Respiratory 
Distress Syndrome (ARDS).  
Protocol Date:  FINAL  Amendment 6 (Version 7)/ 25 September  2020  
 
 
SIGNATURE:  
 
   
Principal Investigator :  Date  
  
Name of Principal Investigator (Please Print)   
 
  
Address of Principal Investigator   
 
The signature of the Principal Investigator constitutes approval of this protocol and an 
assurance that this study will be conducted according to all requirements of this protocol 
and according to Good Clinical Practices (GCP).  